HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hongyan Suo Selected Research

ONC206

1/2022ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer.
1/2021Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hongyan Suo Research Topics

Disease

3Neoplasms (Cancer)
01/2022 - 01/2021
2Endometrial Neoplasms (Endometrial Cancer)
01/2022 - 01/2021
1Ovarian Neoplasms (Ovarian Cancer)
01/2022
1Hematologic Neoplasms (Hematological Malignancy)
01/2021

Drug/Important Bio-Agent (IBA)

2TIC10 compoundIBA
01/2022 - 01/2021
2ONC206IBA
01/2022 - 01/2021
1Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
01/2022
1ipatasertibIBA
01/2022
1Peptide Hydrolases (Proteases)FDA Link
01/2022
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2021
1Dopamine Receptors (Dopamine Receptor)IBA
01/2021
1LigandsIBA
01/2021